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ABSTRACT
Multiple studies, including various methods and overall limited numbers of 
mostly heterogeneous cases, indicate that the level of embryonic stem cell microRNAs 
(miRs) (e.g. 371a-3p, 372-3p, 373-3p, and 367-3p) are increased in serum at primary 
diagnosis of almost all testicular germ cell cancer (TGCC).
Here we determine the status of three of these miRs in serum samples of 250 
TGCC patients, collected at time of primary diagnosis, compared with 60 non-TGCC 
patients and 104 male healthy donors. The levels of miRs were measured by the robust 
ampTSmiR test, including magnetic bead-based miR isolation and target specific pre-
amplification followed by real-time quantitative PCR (RT-qPCR) detection. Calibration 
is performed based on the non-human spike-in ath-miR-159a, and normalization on 
the endogenous control miR-30b-5p.
The serum levels of miR-371a-3p, 373-3p, and 367-3p are informative to 
accurately detect TGCC patients, both seminomas and non-seminomas, at the time 
of primary diagnosis (p< 0.000). Receiver Operating Characteristic (ROC) analysis 
demonstrate that the Area Under the Curve (AUC) for miR-371a-3p is 0.951 (being 
0.888 for miR-373-3p and 0.861 for miR-367-3p), with a sensitivity of 90%, and a 
specificity of 86% (positive predictive value of 94% and negative predictive value of 
79%). Inclusion of miR-373-3p and 367-3p resulted in a AUC of 0.962, with a 90% 
sensitivity and 91% specificity. Similar results were obtained using the raw Ct data. 
Importantly, the results demonstrate that ampTSmiR is not suitable to detect pure 
teratoma as well as the precursor of TGCC, i.e., Germ Cell Neoplasia In Situ (GCNIS).
The largest series evaluated so far, demonstrate that detection of the embryonic 
stem cell miR-371a-3p, 373-3p and 367-3p is highly informative to diagnose patients 
with a primary TGCC.
INTRODUCTION
Testicular germ cell cancers (TGCC) are rare in 
the general population, but represent the most common 
malignancies in Caucasian men aged 20-40 years [1]. 
TGCC are a clinically and pathologically heterogeneous 
group of malignancies. TGCC arise from the precursor 
lesion Germ Cell Neoplasia In Situ (GCNIS) [2]. The 
former nomenclature was carcinoma in situ cells, which 
closely resembles embryonic germ cells, either primordial 
germ cells or gonocytes [3]. GCNIS can progress into 
seminomas (SE) and non-seminomas (NS). The NS can 
consist of the histologic subtypes embryonal carcinoma 
(EC), yolk sac tumor (YST), teratoma (TE), and 
choriocarcinoma (CH) [1, 3–7]. Cure rate is over 90% 
of SE patients (independent of stage), and 100% for low 
stage I and II disease, and about 70% for stage III and IV 
disease. For NS patients cure rate is 95% in stage I and II, 
and approximately 70% for stage III and IV disease [8, 9].
TGCC patients have years or even decades after 
the initial diagnosis a risk of developing a second TGCC 
or progression of the disease. Therefore, they require 
                                                         Research Paper
Oncotarget58038www.impactjournals.com/oncotarget
intensive and long term follow-up after diagnosis and 
treatment. For primary diagnosis and follow-up, various 
approaches are currently used, including monitoring the 
diagnostic/follow-up serum-markers α-fetoprotein (AFP), 
human chorionic gonadotropin subunit beta (hCGB), and 
to a lesser extent, because of lower specificity, lactate 
dehydrogenase (LDH) [10]. Approximately 80% of the 
NS, and 20% of the SE show increased levels of the 
serum markers. The serum levels of AFP and hCGB are 
informative to distinguish the good, intermediate and poor 
risk NS group in the metastatic setting. AFP is primarily 
related to the presence of a YST component and hCGB 
to a CH component in the tumor, while they show little 
sensitivity for the SE and EC components. Therefore, a 
significant number of TGCC patients without YST and 
CH, will be negative for these serum markers. In addition 
false high hCGB levels may be induced by chemotherapy 
or marijuana use and false AFP levels due to liver damage 
or disease [10, 11]. Positivity for the markers can also 
change during disease progression, due to different 
histology of the metastasis compared with the primary 
cancer. These shortcomings significantly limit their 
clinical applicability. Therefore, reliable biomarkers with 
a better sensitivity are needed, especially markers related 
to presence of SE and EC.
miRNAs (miRs) are small non-coding RNA 
molecules of approximately 18–25 nucleotides in 
length, involved in post-transcriptional gene regulation, 
by the induction of mRNA degradation or inhibition of 
protein translation [12]. miRs are involved in several 
essential biological processes including cell development, 
differentiation, and diseases. miRs are highly tissue 
specific and play a key role in differentiation and 
maintenance of tissue identity. However, the function of 
most miRs has still to be unraveled. Dysregulation of miRs 
has been linked to cancer development and progression 
[13]. In addition, miRs have been identified in many 
studies as novel diagnostic and prognostic biomarkers 
and are highly stable in body fluids, including serum, and 
can survive unfavorable physiological conditions such 
as multiple freeze–thaw cycles, extended storage, and 
extreme variations in temperature and pH [14]. In addition, 
body fluid-based biomarkers are attractive because of the 
ease and minimal invasiveness of collecting multiple 
samples to monitor actual disease state.
Earlier research studies identified specific embryonic 
stem cell miR-371-3 cluster and miR-302a-d/367 cluster 
as characteristic tissue and serum biomarkers for GCC, 
including those of the testis [15–18]. The miR-371/3 
and miR-302/367 clusters are for sure expressed in SE/
EC/YST and are epigenetically silenced in adult somatic 
cells as well as TE [19–22], most likely irrespective of 
the anatomic site of the tumor and patient age, with TE 
as the only exception [16, 17]. CH has not been evaluated 
separately so far.
In the current study, we examined the levels of 
miR-371a-3p, 373-3p and miR-367-3p in serum samples 
of the largest series of TGCC patients at time of primary 
diagnosis in comparison with non-germ cell cancer 
(NGCC) patients with other testicular abnormalities and 
male adult healthy controls. The results demonstrate 
that miR-371a-3p, 373-3p and 367-3p are significantly 
elevated in sera of patients with a TGCC. In fact, miR-
371a-3p alone is highly informative to diagnose patients 
with a primary TGCC compared to a healthy control group 
with a Receiver Operating Characteristic (ROC) Area 
Under the Curve (AUC) of 0.951, with a sensitivity and 
specificity of 90 and 86%, respectively. The positive and 
negative predictive values are 94% and 79%. Combining 
the three targets results in a AUC of 0.962 and a sensitivity 
and specificity of 90 and 91%.
RESULTS
Comparison of embryonic miR levels between 
TGCC, NGCC, and healthy individuals
The primary goal of this study was the further 
optimization of a previously reported detection 
method for miR in serum (TSmiR test) [15, 23], and 
to demonstrate the power of the adjusted protocol 
(ampTSmiR test) for the primary diagnosis of TGCC 
patients. For this purpose an amplification step and 
stringent quality check has been included. In brief, 
the levels of three preselected miRs (miR-371a-3p, 
miR-373-3p and miR-367-3p) were determined in a 
RT-qPCR assay after a magnetic bead-based isolation 
and a targeted pre-amplification step. In spite of some 
differences in the detection of the spike-in targets 
(n>400, SD<0.84, coefficients of variation less than 
7.1%)(Supplementary Figure S1A), calibration with 
these spike-ins had minor effects on the levels of the 
reference miRs (Supplementary Figure S1B) (see 
Materials and Methods for further details). Therefore, 
the measured levels were calibrated to the non-human 
spike-in ath-miR-159a only. The reason for omitting the 
cel-miR-39-3p as target for calibration, as previously 
included [15] is to simplify the pipeline, because 
inclusion of multiple targets for calibration had no 
additional value (data not shown). Unexpectedly, a 
significant and relative large difference in detection 
levels of the reference miR-93 was observed between 
the TGCC and HD group, compared with miR-30b-5p 
(Supplementary Figure S1C and S1D). In fact, the HD 
showed a significant lower level compared with both 
of the affected groups (GCC and NGCC, p<0.000). 
This observation could not be made in our previous 
study [15], because no HD group was included. As 
a consequence, our previous approach, based on 
normalization of the median of both miR-30b-5p and 
miR-93, resulted in a minor reduction on separation 
of patients and HD compared with the use of miR-
30b-5p only (AUC scores improved from 0.937 to 
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0.951) (data not shown). Therefore in contrast to our 
earlier publication [15], miR-93 has been excluded for 
normalization in this study, and the miR levels were 
normalized to miR-30b-5p, proven to be a reliable stable 
miR in serum [23]. This protocol, i.e., the ampTSmiR 
test, was applied to a unique series of sera at the time 
of primary diagnosis from 250 TGCC patients, 60 
NGCC patients and 104 HD. The overlap of cases with 
the earlier study [15] is specified in the Materials & 
Methods section. Comparison of the analyses indicated 
similar results but a higher specificity, which shows the 
additional value of the improved protocol regarding 
calibration, normalization and the additional use of an 
amplification step in the pipeline. The miR levels from 
the cohort of 250 sera from TGCC patients, including 
110 NS, 128 SE, six TE and six GCNIS, 60 NGCC 
patients and 104 male HD were compared. Box plots of 
relative levels of circulating miRs are depicted in Figure 
1 and in principal component analysis (PCA) plots 
(Supplementary Figure S2). A clear separation of TGCC 
and HD by levels of miR-371a-3p, 373-3p and 367-3p 
was observed (each p < 0.000). NGCC and HD were 
significantly separated by levels of miR-371a-3p, 367-
3p, and by miR-373-3p as well (p < 0.000). Importantly, 
sera of TGCC and NGCC patients were separated by 
levels of the three miRs (each p < 0.000) (Figure 1). As 
expected, the highest levels of the miRs were observed 
in sera of TGCC patients (Figure 1). A positive relation 
was observed between tumor size and levels of miR-
371a-3p in patients with known stadium I TGCC, both 
SE and NS (n = 72, Pearson correlation 0.429, p<0.000), 
in agreement with a recent study [24] (Supplementary 
Table 1). Also a relation was observed for levels of miR-
373-3p and miR-367-3p and tumor size in patients with 
stadium I TGCC. This correlation was lost in case of 
proven metastatic disease, for the total group as well for 
the SE and NS patients specifically.
Diagnostic information of the serum based miR-
371a-3p, 373-3p and 367-3p were determined by 
receiver operating characteristic (ROC) analysis
A ROC curve was generated for each miR separately 
(Figure 2A) and the various combinations of the miRs 
(Figure 2B). Area under the curve (AUC) for miR-371a-
3p was 0.951 for the comparison of TGCC with HD, 
being 0.888 for miR-373-3p and 0.861 for miR-367-3p. 
The list of subgroups with confidence intervals is indicated 
in Supplementary Table S2, and partly represented in 
Figure 2. Combination of miR-371a-3p, 373-3p and 
367-3p resulted in a AUC of 0.962. Separation of TGCC 
in NS and SE cases gave similar results with slightly 
higher AUC values for NS patients for the individual 
targets, most likely caused by higher levels in NS serum 
samples compared with sera of SE patients (Figure 2C 
and 3). Levels of miR-367-3p were significantly higher 
in NS compared with SE serum samples (p <0.000). Of 
notice is that the RAW data (i.e., without calibration or 
normalization) gave the similar significant separation of 
TGCC patients and HD based on the individual targets 
(Supplementary Figure S3)
Cut-off points were calculated with the 
optimal balance between sensitivity and specificity 
(Supplementary Table S2, indicated with an asterisk). For 
miR-371a-3p comparison of TGCC with HD resulted in 
a sensitivity of 89% and a specificity of 90%. For miR-
373-3p a sensitivity of 70% and specificity of 89% was 
reached. For miR-367-3p the sensitivity was 79%, with 
a specificity of 85%. The combination of all three miRs 
resulted in a sensitivity of 92% and a specificity of 91%. 
Inclusion or exclusion of specific targets besides miR-
371a-3p has minor effect. Sensitivity and specificity were 
also calculated when set at 90% (Supplementary Table 
S2). Positive predictive value (PPV) calculated for the best 
discriminating miR, being miR-371a-3p, was 94% and a 
negative predictive value (NPV) of 79% with a sensitivity 
of 90 and specificity of 86%.
Comparison of circulating miR levels between 
GCNIS, TE patients and healthy individuals
This random selected series of sera contained 
six cases of GCNIS only (i.e., no invasive component 
identified) and six cases of pure mature TE. GCNIS 
showed similar levels of miR-371a-3p and 373-3p and 
higher levels of miR-367-3p (p = 0.017) compared with 
HD (Figure 4). TE related samples showed higher levels 
of miR-371a-3p (p = 0.001), miR-373-3p (p = 0.002) and 
miR-367-3p (p = 0.007) than HD (Figure 4). Although the 
number of cases investigated is low, the results already 
indicate that it is unlikely that GCNIS or TE only can be 
diagnosed based on the ampTSmiR test, due to the small 
differences of the miR levels. This is further strengthened 
by a single case diagnosed as GCNIS only in the testis, 
based on pathological classification, although the matched 
serum showed elevated levels of all three miRs. Review 
of the clinical data, indicated lung and para aortic lymph 
node metastases with high levels of hCGB, supportive for 
a metastatic TGCC. This case, based on these data, was 
therefore included in the TGCC cohort investigated.
Comparison of serum miR levels between NGCC 
and TGCC
The series contained 60 sera of a heterogeneous 
group of NGCC cases. Within this group, the testes were 
removed or biopsied for various reasons, in most cases 
suspicion of a testicular cancer. As shown in Figure 1, 
Supplementary Figure S1B, and Supplementary Table 
S2 separation of TGCC and NGCC is less perfect than 
separation of TGCC and HD. To address the question 
whether this was caused by a specific subgroup, boxplots 
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Figure 1: Detection of TGCC by serum levels of tumor associated miRs. Boxplots of the relative serum levels is presented of 
A. miR-371a-3p, B. 373-3p and C. 367-3p of TGCC (n = 238), NGCC (n = 60) at diagnosis, and HD (n =104). Serum levels of A. miR-
371a-3p, B. miR-373-3p, and C. miR-367-3p discriminate patients with TGCC from those with NGCC and HD. The box marks the first and 
third quartiles. Horizontal lines mark median values, circles are outliers, far outliers are indicated with an asterisk. The whiskers are defined 
as 1.5 times the interquartile range. (**) p<0.000, Mann-Whitney U Test. Abbreviations: TGCC: testicular germ cell cancer; NGCC: non 
germ cell cancer; HD: healthy donor.
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were generated and statistical analysis was performed 
(Figure 5). Although the number of samples in the 
different subgroups is relatively small, some subgroups 
show significantly different results compared with the 
samples of the HD. For example, higher levels of miR-
371a-3p were found in cases with no malignancy (NM), 
torsio testis (TT), Leydig cell tumor (LCT), and B-cell 
lymphoma (BCL). miR-373-3p was elevated in NM, LCT, 
and BCL only. miR-367-3p was elevated in cases with 
NM, LCT, and BCL. For the comparison of the subgroups 
with TGCC, the five cases with BCL showed similar levels 
of each miR. No differences related to the normalization 
target(s) were however identified (see above).
DISCUSSION
miRs detected in serum have been described as 
informative for both diagnosis and prognosis of TGCC. 
Various small scale studies have been performed 
using different approaches and heterogeneous patient 
cohorts. The first case report of Murray et al. [25] 
used conventional RNA isolation in combination with 
multiplexed, high throughput cDNA synthesis and 
quantification of serum miRs. All eight main miRs of the 
miR-371/3 and miR-302/367 clusters were highly elevated 
in the serum of a four-year-old boy at the time of diagnosis 
of a malignant YST. Levels fell during chemotherapy and 
returned to normal during an uneventful clinical follow-
up. Another study [26] investigated sera of six SE and five 
NS patients with stage I disease before orchiectomy and 
five days post-operative and compared with sera of twelve 
healthy males. The pre-operative serum levels of the miRs 
371a-3p, 372-3p and 373-3p were found to be higher 
than the levels detected in controls, and all declined after 
treatment. In addition, only two of the patients included 
had elevated levels of the classical serum markers. In 
two studies by Dieckmann and Spiekermann et al. [27, 
28] the miRs of the miR-371/3 cluster were quantified 
in serum samples of 24 TGCC patients before and after 
treatment. In all patients, serum levels of miRs 371-
Figure 2: Receiver operating characteristic (ROC) plot. A. Diagnostic accuracy of circulating miR-371a-3p, 373-3p and 367-3p 
were analyzed by ROC curves. The data shown in Figure 1 were used to draw the ROC plots. The Area Under the Curve (AUC) varied 
from 0.861 to 0.951. B. ROC curves generated of combinations of the different miR analyses. The AUC varied from 0.915 to 0.962 for 
combination of the miRs. C. ROC analysis generated separately for sera of SE and NS patients. The AUC varied from 0.920 to 0.968 for 
NS and from 0.809 to 0.957 for SE.
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3-3p were elevated compared to controls and dropped 
after orchiectomy. In cases with advanced disease levels 
dropped to the normal range after completion of treatment. 
The levels of miR-371a-3p were not correlated with the 
levels determined in the primary cancer tissue. This is in 
line with a previous study from our group [22].
Another study from our group provided evidence 
that the serum levels of the selected embryonic specific 
miRs is informative to detect a TGCC in the majority of 
cases for initial diagnosis, outperforming the classical 
protein serum markers hCGB and AFP [15]. A miR-
specific para-magnetic bead capture system was used 
Figure 3: Boxplots of the relative serum levels. A. miR-371a-3p, B. miR-373-3p, and C. miR-367-3p of NS (n = 110), SE (n = 128), 
and HD (n =104). For comparison of the levels of each miR in serum of NS or SE with HD: p<0.000, Mann-Whitney U Test. Abbreviations: 
NS: non-seminoma; SE: seminoma; HD: healthy donor.
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to isolate and purify miRs from serum with subsequent 
RT-qPCR. The Targeted serum miR (TSmiR) test was 
applied to five independent serum sample series including 
80 TGCC, 47 controls, 11 matched pre- and post-
orchidectomy samples and 12 NGCC testicular masses. 
These cases had overlap with the previous studies from 
the UK and Germany, showing similar observations, 
supporting the informativity of the TSmiR test. TGCC 
serum samples showed a significant increase of miR-371-
3/367-3p levels. miR serum levels returned to normal 
Figure 4: miR levels in individuals with pure Germ Cell Neoplasia in situ (GCNIS), or teratoma (TE). Boxplots of the 
relative serum levels of A. miR-371a-3p, B. 373-3p and C. 367-3p of patients with GCNIS (n = 6), TE (n = 6), and HD (n =104). p-values, 
Mann-Whitney U Test. Abbreviations: n.s. non-significant.
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Figure 5: miR levels in individuals with testicular disease. Boxplots of the serum levels of A. miR-371a-3p, B. miR-373-3p, and 
C. miR-367-3p of NGCC subgroups, HD (n =104), and TGCC (GCC) patients (n = 236). Abbreviations: NM, no malignancy (n = 20); 
TT, torsio testis (n = 8); Inf, inflammation (n = 12); LCT, Leydig cell tumor (n = 8); BCL, B-cell lymphoma (n = 5); n.s. non-significant. 
p-values, Mann-Whitney U Test.
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levels after orchidectomy (similar cases as reported before 
[26]). Furthermore, there was a trend toward higher miR 
levels in patients with disseminated disease. The TSmiR 
test showed an overall sensitivity of 98%, and a specificity 
of 48% (control versus cancer), based on combination of 
the different miRs, outperforming the serum markers AFP 
and hCGB. Also Syring et al. [29] reported that miR-
371a-3p outperformed AFP and hCGB in detection of 
TGCC. Recently a robust pipeline was described, using 
total RNA isolation and pre-amplification, for detection of 
miR-371-3p and 367-3p in sera and cerebrospinal fluid of 
25 pediatric GCC patients [23]. The method showed high 
sensitivity and specificity for the diagnosis of extracranial 
GCC. It allowed early detection of relapse in one patient 
with a GCC and distinguished intracranial GCC from 
intracranial non-GCC at diagnosis.
So far, in total more than 130 serum samples of 
TGCC and over 70 controls have been evaluated, although 
with different protocols. This makes a proper conclusion 
regarding the value of the test difficult, especially in 
the context of the used heterogeneous control samples. 
Therefore, amongst others, the present study was 
undertaken, including the largest series of sera from 
primary TGCC patients (i.e., n = 250), including both 
SE and NS, were compared with sera from male HD (n 
= 104) and sera from NGCC (n = 60). In addition to the 
miR-specific paramagnetic bead capture, pre-amplification 
of the cDNA was added to the pipe-line to increase 
sensitivity and specificity. The results demonstrate that 
sera from both NS and SE could be separated with high 
sensitivity and specificity from sera of HD by levels of 
miR-371a-3p, 373-3p and 367-3p (Supplementary Table 
S2). This means that the ampTSmiR test is an important 
new tool in the clinical management of TGCC. A possible 
shortcoming of the study could be the difference in age 
between the subgroups, especially the additional healthy 
control group, being healthy blood donors (HD) (see 
Materials & Methods section for more details). However, 
no relation between age and miR levels in the different 
subgroups was identified, and therefore concluded that the 
HD is a relevant and informative subgroup in the context 
of the study performed.
Interestingly, we observed higher levels of the 
selected embryonic miRs in some subgroups of NGCC 
but with other testis abnormalities. This is in line with 
a relatively low level of these miRs in normal testis, 
as we reported before [17]. However, the mechanisms 
resulting in the release of these miRs is unknown. Several 
possibilities have been suggested, including passive 
leakage from damaged cells, due to tissue injury, chronic 
inflammation, necrosis or active secretion via micro-
vesicles, including exosomes [14]. In this context, it is 
of notion that in our series no increased miR levels were 
observed in cases with inflammation or necrosis, including 
torsio testis for miR-373-3p and miR-367-3p. In contrast, 
in cases of Leydig cell tumor and B-cell lymphoma 
increased levels of miR-371a-3p, 373-3p and 367-3p were 
observed in serum. To rule out that this was caused by 
normalization, a boxplot was generated showing the levels 
of miR-30b-5p in sera of the various patients, i.e., TGCC, 
HD, and NGCC split in malignancy and no malignancy 
(Supplementary Figure 1E). In spite of presence of a 
minor difference between HD and TGCC (0.6 Ct), and HD 
and NGCC (0.9 Ct) (Figure S2C), no significant difference 
was observed between the NGCC group split in malignant 
and non-malignant. The increased miR levels may give a 
problem in differential diagnosis under certain conditions, 
therefore biopsy remains the golden standard in suspected 
cases, like in case of a mono-testis. In that particular 
situation the direct enzymatic alkaline phosphatase 
reactivity staining might be informative to be included to 
prevent a second operation [30]. Although it needs further 
investigation, our preferred hypothesis is that the elevated 
levels are explained by a disturbed integrity of the testis. 
Cellular stress might be the cause of the elevated serum 
miR levels in these patients with testicular complaints. 
The group with inflammation contained one patient with 
inflammation of the testis and the others suffered from 
epididymitis, which did not disturb the integrity of the 
testis. This finding must be kept in mind in the context 
of the use of these miR for primary diagnosis of a TGCC.
Several risk factors for development of TGCC 
have been identified. Both high and low birth weight, 
cryptorchidism, inguinal hernia, twinning, and gestational 
age are factors influencing the risk of development 
of a TGCC [31]. Also patients with Disorders of Sex 
Development are at risk for gonadal, including TGCC 
[32]. It would be most useful to identify patients at a very 
early stage of the disease (GCNIS) within the groups with 
an increased risk using a non-invasive test.
So far, all results indicate that the selected miRs 
are present in seminoma and all the different histological 
elements of non-seminoma (except teratoma), i.e., 
embryonal carcinoma, yolk sac tumor and choriocarcinoma 
[15, 23] and unpublished observations. The data presented 
here indicate that the ampTSmiR assay as performed will 
not be able to detect the single presence of the precursor 
lesion GCNIS as well as pure teratoma both at primary 
diagnosis as well as during follow up. The first entity is of 
relevance, because it will allow identification of patients 
with the presence of invasive disease, independent of 
the histological composition, except pure teratoma, both 
seminoma as well as (mixed) non-seminoma. This is nicely 
demonstrated by the single patient with elevated miRNA 
levels and only GCNIS at pathological examination of 
the suspected testis, but evidence of metastatic disease 
with lung and para-aortic lymph node metastases and 
raised levels of HCG, consistent with a malignant GCT. 
The putative second limitation of the assay, i.e., failure to 
detect pure TE in contrast to the non-teratomatous non-
seminomatous elements (EC, YST, CH), is of importance 
for the role of the ampTSmiR assay in a clinical setting as 
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well. The inability to detect pure TE compared to the other 
nonseminomatous elements might be highly beneficial of 
the test in daily practice. High throughput miR profiling 
experiments are currently ongoing to identify TE specific 
informative miRNA targets, although it is unlikely 
that these will be found based on the pure somatic 
differentiation. In other words, additional biomarkers will 
be required for this specific entity.
We observed a significant correlation between the 
level of the target miRNAs and the size of the primary 
lesion in stage I disease, both seminoma and non-
seminoma, independent of histological composition. This 
correlation is lost in case of metastatic disease both for 
seminoma and non-seminoma. Further investigation of 
this finding, in line with an independent recent publication 
[24], might result in the level of serum miRNA as 
predictor of the presence of metastatic disease in case the 
size of the primary GCC is known. This is currently under 
investigation. Moreover, it will be of relevance in case of 
marker negative GCC, found to be the case in 20% of the 
NS and 80% of the SE patients. It is not expected that, 
besides TE, seminoma or the other histological component 
of non-seminoma will become negative for these miRNA 
upon further clinical progression. This is based on the 
intrinsic characteristics of these markers for the embryonic 
status of the GCC (non-TE) elements. In addition, pure 
TE are, so far, found to be overall negative for the miRs 
as identified. In this study moderately elevated levels were 
however found, likely due to the increased sensitivity of 
the assay. The impact of detection of pure TE in a clinical 
setting requires further investigations, which are currently 
ongoing. The overall negative pattern is expected, based 
on loss of the embryonic characteristics of this specifically 
and completely somatically differentiated histology, to be 
independent of anatomic localization. This fact might 
be informative in the clinical context of prediction of a 
non-TE (malignant) component in metastases, both under 
active surveillance as well as systemic treatment (either 
irradiation of chemotherapy). With a single exception [23], 
no further data is available related to growing teratoma, 
as well as non-germ cell malignant progression, which 
is a topic of current investigation. Moreover, as briefly 
indicated above, the ampTSmiR test might also be highly 
informative in the context of extragonadal GCC, again of 
the various histological compositions, likely except pure 
TE. Supportive data for this assumption has been recently 
published, indicating that the target miR to be determined 
whether in serum or cerebrospinal fluid is informative 
for intracranial GCC as well [23]. To answer these 
clinically highly relevant questions, it will be necessary 
to perform additional, preferentially multicenter, both 
retrospective as well as prospective studies. Therefore, 
comparative analyses of the profile of the miRs and the 
standard serum biomarkers (at least AFP and hCGB) as 
well as clinical data need to be included to decide upon 
the additional value of the ampTSmiR assay for both the 
initial diagnosis and follow up. For this it is of relevance 
that the ampTSmiR pipeline is composed of a defined set 
of commercially available components. Therefore it is 
expected that implementation of the ampTSmiR pipeline 
will be possible for diagnostic departments with expertise 
on (molecular) biomarker assays in body fluids.
In conclusion, we demonstrate that the serum-
based ampTSmiR test is highly sensitive and specific 
in the identification of TGCC patients compared to HD 
and patients with non-cancerous testicular diseases. Our 
next step in this analysis is identification of recurrent or 
relapsed disease, for which the collected samples, both 
retrospectively as well as prospectively, are currently 
under evaluation.
MATERIALS AND METHODS
Clinical samples
The study is approved by the institution’s Medical 
Ethical Committee (MEC 02.981 and CCR2041). We 
adhere to the “Code for Proper Secondary Use of Human 
Tissue in The Netherlands” developed by the Dutch 
Federation of Medical Scientific Societies (FMWV 
(Version 2002, update 2011). Serum samples were 
collected between January 2003 and July 2015, and stored 
after primary handling at -80 °C. In total, 250 serum 
samples of patients with a primary TGCC ((128 SE, 
median age was 36 (range 21-72 years), 110 NS, median 
age 29 (range 17-63 years), six TE (median age 29.5 
(range 16-65 years), and six GCNIS only (median age 24.5 
(range 12-51 years)) were included. miR levels of TGCC 
patients were compared with 104 sera of male healthy 
donors, median age 54 (range 26-69 years), and 60 sera 
of patients with various non-TGCC abnormalities of the 
testis (median age 44 (range 13-81 years). The latter group 
consisted of the following variants: NM (no malignancy; n 
= 20); TT (torsio testis; n = 8); Inf (inflammation; n = 12); 
LCT (Leydig cell tumor; n = 8); BCL (B-cell lymphoma; 
n = 5). The normal control serum samples were obtained 
from Sanquin (Amsterdam, the Netherlands). In total 66 of 
the 414 serum samples overlap with our earlier presented 
study [15].
miRNA purification and quantitative real-time 
PCR (RT-qPCR)
Specific miRs were isolated from 50 μl serum 
using target specific anti-miR magnetic beads as 
described before [15], with the following modifications. 
A MagMax™ Express-96 robot with TaqMan® miRNA 
ABC Purification Kits, panel A, was used to isolate the 
miRs, as per manufacturer's instructions (Thermo Fisher 
Scientific, Bleiswijk, the Netherlands). cDNA generation 
and quantification of miR levels was performed using 
the various TaqMan MicroRNA assays (Thermo Fisher 
Oncotarget58047www.impactjournals.com/oncotarget
Scientific): catalog ID: hsa-miR-371a-3p (002124); 
hsa-miR-373-3p (000561); has-miR-367-3p (000555); 
ath-miR-159a (000338); cel-miR-39-3p (000200); hsa-
miR-93 (000432); hsa-miR-30b-5p (000602). In brief 5 
μL of specifically targeted purified miR in elution buffer 
was reverse transcribed into miR specific cDNA with a 
TAQMAN(R) MICRORNA RT KIT (Thermo Fisher 
Scientific), followed by a 12 cycle pre-amplification step 
using 2x TaqMan Preamp Master mix (4488593, detailed 
protocol by supplier Thermo Fisher Scientific) and 20x 
TaqMan MicroRNA Assays. Thermal-cycling conditions: 
95 °C for 10 min., followed by 12 cycles of 95 °C for 15 
sec. and 60 °C for 1 min. miR levels were determined in1.5 
μl of cDNA on a TaqMan 7500 Real-Time PCR system, 
according to the supplier (Thermo Fisher Scientific).
Quality control
All sera were visually inspected and hemolytic 
samples were discarded from analysis. Two non-human 
miR spike-ins ath-miR-159a and cel-miR-39-3p were 
added in the same fixed amount to the sera (0.2 ul of a 1 
nM stock solution) for quality control of RNA isolation 
and cDNA generation. The fact that equal quantities of 
ath-miR-159a and cel-miR-39-3p spike-ins do not give 
identical Ct values is not surprising because of multiple 
reasons. These include the production of identical 
concentrations of two different RNA oligo’s (with possible 
differences in quality and requiring over 10,000-fold 
dilution of the original stock) being by definition subject 
to variation; in any quantitative PCR analysis, comparison 
of Ct values (and as such derived levels) between different 
targets is not directly informative because of potential 
differences in efficiencies of both the RT-reaction and the 
actual amplification (PCR). The absolute Ct values for 
these spike-ins is therefore of no importance, but, they 
should be recovered and detected stably and reproducibly. 
Based on the data presented in the manuscript this is 
the case, since the variation in Ct for these spike-ins is 
generally within +/- 1 Ct of the average (N>400, SD<0.84 
for both, Coefficients of variation are less than 7.1%). 
Pearson correlation between the results obtained from 
these spike-ins is 0.367. The relative low correlation 
is explained by the very small window of variation. 
Therefore, for calibration of input levels ath-miR-159a 
was used in order to correct for possible differences in 
efficiency of the RNA extraction and cDNA generation 
(Supplementary Figure S1A). No samples had to be 
excluded due to poor miRNA recovery. For normalization 
the mean levels of the endogenous reference miR (miR-
30b-5p) was used as described before [15, 23]. The 
miR-93 was omitted for reasons indicated in the Results 
section. Relative expression is depicted as median dCt of 
all HD minus dCt miR of interest. In each cDNA synthesis 
experiment, 10-fold dilution series of purified miR of the 
TCam-2 seminoma cell line was included for quality 
control and qPCR efficiency and interplate calibration. For 
negative control, the no template control, elution buffer 
was added instead of purified miR.
Statistical analysis
Data processing and statistical analysis was 
performed using Microsoft Excel 2010, IBM SPSS 
statistics V21.0, and GenEx 6 (MultiD). Inter-group 
differences were compared using the Mann-Whitney 
U test. A p value of <0.05 was considered statistically 
significant. All p values are two-tailed. Receiver 
operating characteristic (ROC) curves were generated 
to calculate the area under the curve (AUC), with 95% 
confidence intervals (CI), and the diagnostic value 
including sensitivity and specificity. The estimated 
functions of combined markers were constructed using 
binary logistic regression. The optimum cut-off value 
for diagnosis was achieved by maximizing the sum of 
sensitivity and specificity, (square root of [1-sensitivity]2 
+ [1-specificity]2), by minimizing the distance of the cut-
off value from the top-left corner of the ROC curve and 
the maximum distance to the random chance line (Youden 
index).
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